Anavex Life Sciences Corp (AVXL)

[rx7171]

This is true.
All treated patient AD symptoms will progress.
The rate of progress is slowed, in the case of the 70-80% of those with the wild type sigma-1 slowed on average 49.8% which is a huge improvement not a cure. Adding years of cognitive and functional independence.

What we need to find out is what happens when Blarcamasine is administered prior to any overt symptoms of AD appear.
Delaying even the onset of symptoms 5-10 years would be huge, possibly delaying them into an advanced age when other ailments become terminal.

However that could also be pushed far into the future since the action of Blarcamasine on Sigma-1 in multiple critical organs has the potential to slow their biological aging.